572 related articles for article (PubMed ID: 28783452)
41. Herpesvirus infections in hematopoietic stem cell transplant recipients seropositive for human cytomegalovirus before transplantation.
Fan J; Jing M; Yang M; Xu L; Liang H; Huang Y; Yang R; Gui G; Wang H; Gong S; Wang J; Zhang X; Zhao H; Gao H; Dong H; Ma W; Hu J
Int J Infect Dis; 2016 May; 46():89-93. PubMed ID: 27057748
[TBL] [Abstract][Full Text] [Related]
42. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.
Gerbitz A; Gary R; Aigner M; Moosmann A; Kremer A; Schmid C; Hirschbuehl K; Wagner E; Hauptrock B; Teschner D; Roesler W; Spriewald B; Tischer J; Moi S; Balzer H; Schaffer S; Bausenwein J; Wagner A; Schmidt F; Brestrich J; Ullrich B; Maas S; Herold S; Strobel J; Zimmermann R; Weisbach V; Hansmann L; Lammoglia-Cobo F; Remberger M; Stelljes M; Ayuk F; Zeiser R; Mackensen A
Front Immunol; 2023; 14():1251593. PubMed ID: 37965339
[TBL] [Abstract][Full Text] [Related]
43. Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies.
Quach DH; Lulla P; Rooney CM
Blood; 2023 Feb; 141(8):877-885. PubMed ID: 36574622
[TBL] [Abstract][Full Text] [Related]
44. High-intensity interval training in allogeneic adoptive T-cell immunotherapy - a big HIT?
Heinemann NC; Tischer-Zimmermann S; Wittke TC; Eigendorf J; Kerling A; Framke T; Melk A; Heuft HG; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
J Transl Med; 2020 Apr; 18(1):148. PubMed ID: 32238166
[TBL] [Abstract][Full Text] [Related]
45. Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation.
Ip W; Silva JMF; Gaspar H; Mitra A; Patel S; Rao K; Chiesa R; Amrolia P; Gilmour K; Ahsan G; Slatter M; Gennery AR; Wynn RF; Veys P; Qasim W
Cytotherapy; 2018 Jun; 20(6):830-838. PubMed ID: 29753677
[TBL] [Abstract][Full Text] [Related]
46. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
[TBL] [Abstract][Full Text] [Related]
47. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.
Uhlin M; Gertow J; Uzunel M; Okas M; Berglund S; Watz E; Brune M; Ljungman P; Maeurer M; Mattsson J
Clin Infect Dis; 2012 Oct; 55(8):1064-73. PubMed ID: 22806594
[TBL] [Abstract][Full Text] [Related]
48. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
Sili U; Leen AM; Vera JF; Gee AP; Huls H; Heslop HE; Bollard CM; Rooney CM
Cytotherapy; 2012 Jan; 14(1):7-11. PubMed ID: 22172091
[TBL] [Abstract][Full Text] [Related]
49. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
[TBL] [Abstract][Full Text] [Related]
50. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay.
Inazawa N; Hori T; Nojima M; Saito M; Igarashi K; Yamamoto M; Shimizu N; Yoto Y; Tsutsumi H
J Med Virol; 2017 Feb; 89(2):358-362. PubMed ID: 27364410
[TBL] [Abstract][Full Text] [Related]
51. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.
Withers B; Blyth E; Clancy LE; Yong A; Fraser C; Burgess J; Simms R; Brown R; Kliman D; Dubosq MC; Bishop D; Sutrave G; Ma CKK; Shaw PJ; Micklethwaite KP; Gottlieb DJ
Blood Adv; 2017 Nov; 1(24):2193-2205. PubMed ID: 29296867
[TBL] [Abstract][Full Text] [Related]
52. Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation.
Shafat MS; Mehra V; Peggs KS; Roddie C
Front Immunol; 2020; 11():1694. PubMed ID: 32849591
[TBL] [Abstract][Full Text] [Related]
53. Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation.
Lee SS; Ahn JS; Jung SH; Ahn SY; Kim JY; Jang HC; Kang SJ; Jang MO; Yang DH; Kim YK; Lee JJ; Kim HJ
Korean J Intern Med; 2015 Mar; 30(2):212-8. PubMed ID: 25750563
[TBL] [Abstract][Full Text] [Related]
54. [Clinical study of mesenchymal stem cells from third-party donors in the treatment of refractory late onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplanation].
Zhao K; Huang F; Chen XY; Chang Y; Xu N; Shi PC; Liu H; Sun J; Xiang P; Liu QF; Fan ZP
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):488-493. PubMed ID: 35968592
[No Abstract] [Full Text] [Related]
55. Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.
Baugh KA; Tzannou I; Leen AM
Curr Opin Infect Dis; 2018 Aug; 31(4):292-300. PubMed ID: 29750672
[TBL] [Abstract][Full Text] [Related]
56. Virus-specific T-cell therapies for patients with primary immune deficiency.
Keller MD; Bollard CM
Blood; 2020 Feb; 135(9):620-628. PubMed ID: 31942610
[TBL] [Abstract][Full Text] [Related]
57. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
McLaughlin LP; Rouce R; Gottschalk S; Torrano V; Carrum G; Wu MF; Hoq F; Grilley B; Marcogliese AM; Hanley PJ; Gee AP; Brenner MK; Rooney CM; Heslop HE; Bollard CM
Blood; 2018 Nov; 132(22):2351-2361. PubMed ID: 30262660
[TBL] [Abstract][Full Text] [Related]
58. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
Gerdemann U; Vera JF; Rooney CM; Leen AM
J Vis Exp; 2011 May; (51):. PubMed ID: 21654628
[TBL] [Abstract][Full Text] [Related]
59. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
60. Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant.
Khoury R; Grimley MS; Nelson AS; Leemhuis T; Cancelas JA; Cook E; Wang Y; Heyenbruch D; Bollard CM; Keller MD; Hanley PJ; Lutzko C; Pham G; Davies SM; Rubinstein JD
Am J Transplant; 2024 Apr; ():. PubMed ID: 38643944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
